Table 1 ADCs currently approved by the US FDA before December 2021
ADC | Target antigen | mAb isotype | Linker | Payload |
|---|---|---|---|---|
Gemtuzumab ozogamicin (Mylotarg) | CD33 | IgG4 | Cleavable (Hydrazone) | Ozogamicin |
Brentuximab Vedotin (Adcetris) | CD30 | IgG1 | Cleavable (Peptide) | MMAE |
Ado-trastuzumab emtansine (T-DM1) (Kadcyla) | HER2 | IgG1 | Non-cleavable (Thioether) | DM1 |
Inotuzumab Ozogamicin (Besponsa) | CD22 | IgG4 | Cleavable (Hydrazone) | Ozogamicin |
Moxetumomab pasudotox-tdfk (Lumoxiti) | CD22 | IgG1 | Cleavable (Peptide) | PE38 |
Polatuzumab vedotin-piiq (Polivy) | CD79b | IgG1 | Cleavable (Peptide) | MMAE |
Enfortumab vedotin-ejfv (Padcev) | Nectin-4 | IgG1 | Cleavable (Peptide) | MMAE |
Fam-trastuzumab deruxtecan-nxki (T-DXd) (Enhertu) | HER2 | IgG1 | Cleavable (Peptide) | DXd |
Sacituzumab govitecan-hziy (Trodelvy) | TROP2 | IgG1 | Cleavable (Peptide) | SN-38 |
Belantamab mafodotin-blmf (Blenrep) | BCMA | IgG1 | Non-cleavable (Thioether) | MMAF |
Loncastuximab tesirine-lpyl (Zynlonta) | CD19 | IgG1 | Cleavable (Peptide) | SG3199 |
Tisotumab vedotin-tftv (Tivdak) | Tissue factor | IgG1 | Cleavable (Peptide) | MMAE |